Absci Corp
absci.comAbsci Corp (NASDAQ: ABSI) is a clinical-stage biopharmaceutical company that uses an AI-native approach to develop antibody therapeutics. Revenue comes from partner program fees, including up-front fees, research fees, and potential milestone and royalty payments from drug creation collaborations, though the company remains pre-commercial. Partner program revenue was $2.8 million in FY2025, down from $4.5 million in FY2024, while the net loss widened to $115.2 million in FY2025 from $103.1 million in FY2024. The platform combines Origin-1, a generative design model, with a lab-in-the-loop validation system to design antibody-based therapeutics. Lead internal program ABS-201 is advancing toward clinical development, with additional preclinical programs targeted for partnership or out-licensing. As of December 31, 2025, Absci had 140 employees, the majority engaged in research and development. Sean McClain, co-founder and CEO, leads the company alongside CFO and Chief Business Officer Zachariah Jonasson.
Products & Services
Integrated Drug Creation platform combining Origin-1 (generative AI design model) and a lab-in-the-loop wet-lab validation system. Internally developed pipeline led by ABS-201, a clinical-stage antibody therapeutic. Additional preclinical programs generated via de novo antibody design, multi-parameter candidate optimization, and reverse immunology approaches. Partnered programs structured as drug creation collaborations or co-development partnerships.
Revenue Model
Partner program revenue from drug creation collaborations, including up-front fees and research fees, plus potential clinical and commercial milestone payments and royalties. FY2025 partner program revenue was $2.8 million; FY2024 was $4.5 million. The company is pre-commercial on its internally developed pipeline and funds operations primarily from cash reserves and marketable securities.
Customers & Markets
Biopharmaceutical and pharmaceutical partners seeking AI-assisted antibody drug discovery and development. End markets are therapeutic areas with high unmet medical need and underexplored biological mechanisms. The company also pursues out-licensing arrangements for select pipeline assets.
Financial Snapshot
Loading...
